A Phase 1, Open-label Trial of Belzupacap Sarotalocan (AU-011) to Determine the Feasibility and Safety of Intratumoral Injection With or Without Intramural Injection in Subjects With Bladder Cancer
Latest Information Update: 12 Aug 2024
At a glance
- Drugs Belzupacap sarotalocan (Primary)
- Indications Bladder cancer; Urogenital cancer
- Focus Adverse reactions
- Sponsors Aura Biosciences
- 08 Aug 2024 According to an Aura Biosciences media release, company plans to host a virtual urologic oncology investor event featuring key opinion leaders (KOLs) in October 2024. Early NMIBC data from the ongoing Phase 1 trial is expected to be presented at this event.
- 09 May 2024 According to an Aura Biosciences media release, preliminary data from the first patient in the light activated cohort of the trial demonstrated a clinical complete response demonstrated by absence of cancer cells on histopathology with evidence of extensive necrosis and immune activation after a single administration of bel-sar followed by light activation.
- 02 Mar 2024 Planned number of patients changed from 19 to 21.